Taken together, these findings stress the relevance of sexual dimorphism in adaptive immunity, and suggest a plausible benefit to analyzing naïve T cell output in prostate and breast cancer patients treated with LHRH-analogs. This evidence concerns the gene GNRH1 and breast cancer.